Idexx Laboratories Inc IDXX
We take great care to ensure that the data presented and summarized in this overview for IDEXX LABORATORIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IDXX
View all-
Vanguard Group Inc Valley Forge, PA9.86MShares$5.24 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$5.1 Billion0.11% of portfolio
-
State Street Corp Boston, MA3.65MShares$1.94 Billion0.06% of portfolio
-
Terry Smith Fundsmith LLP | London, X02.65MShares$1.41 Billion5.14% of portfolio
-
Geode Capital Management, LLC Boston, MA2.41MShares$1.28 Billion0.08% of portfolio
-
Bamco Inc New York, NY2.06MShares$1.09 Billion2.63% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.99MShares$1.06 Billion0.1% of portfolio
-
Morgan Stanley New York, NY1.66MShares$881 Million0.05% of portfolio
-
Invesco Ltd. Atlanta, GA1.17MShares$620 Million0.1% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.13MShares$598 Million0.28% of portfolio
Latest Institutional Activity in IDXX
Top Purchases
Top Sells
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Insider Transactions at IDXX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 01
2025
|
Michael Perkins Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,499
-38.79%
|
$768,987
$513.36 P/Share
|
Jun 01
2025
|
Michael Perkins Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,382
+46.67%
|
-
|
May 21
2025
|
M Anne Szostak Director |
SELL
Open market or private sale
|
Indirect |
1,260
-41.16%
|
$645,120
$512.34 P/Share
|
May 21
2025
|
M Anne Szostak Director |
SELL
Open market or private sale
|
Direct |
1,046
-79.97%
|
$536,598
$513.74 P/Share
|
May 21
2025
|
M Anne Szostak Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,046
+44.44%
|
$167,360
$160.28 P/Share
|
May 13
2025
|
Daniel M Junius Director |
SELL
Open market or private sale
|
Direct |
2,683
-44.81%
|
$1,357,598
$506.41 P/Share
|
May 13
2025
|
Daniel M Junius Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,683
+20.29%
|
$708,312
$264.69 P/Share
|
May 09
2025
|
Sophie V. Vandebroek Director |
SELL
Open market or private sale
|
Direct |
1,279
-52.29%
|
$627,989
$491.34 P/Share
|
May 09
2025
|
Sophie V. Vandebroek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,279
+34.34%
|
$361,957
$283.59 P/Share
|
May 06
2025
|
Stuart Essig Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+10.49%
|
-
|
May 06
2025
|
Daniel M Junius Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+7.35%
|
-
|
May 06
2025
|
Lawrence D Kingsley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
346
+1.84%
|
-
|
May 06
2025
|
M Anne Szostak Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+50.0%
|
-
|
May 06
2025
|
Sophie V. Vandebroek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+18.33%
|
-
|
Feb 14
2025
|
Michael G Erickson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
177
-0.83%
|
$78,588
$444.53 P/Share
|
Feb 14
2025
|
Michael G Erickson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
557
+0.65%
|
-
|
Feb 14
2025
|
George Fennell Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
133
-1.57%
|
$59,052
$444.53 P/Share
|
Feb 14
2025
|
George Fennell Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
304
+0.9%
|
-
|
Feb 14
2025
|
Nimrata Hunt Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
268
-2.13%
|
$118,992
$444.53 P/Share
|
Feb 14
2025
|
Nimrata Hunt Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+1.74%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 32.9K shares |
---|---|
Bona fide gift | 533K shares |
Grant, award, or other acquisition | 704 shares |
Payment of exercise price or tax liability | 5.63K shares |
---|---|
Open market or private sale | 20.1K shares |
Bona fide gift | 533K shares |